Ramelteon: a novel treatment for the treatment of insomnia

References

• Lynch HJ, Wurtman RJ, Moskowitz MA et al. Daily rhythm in human urinary melatonin. Science184, 169–171 (1975).
   Web of Science ®Google Scholar
• Brzezinski A. Melatonin in humans. N. Engl. J. Med.336, 186–195 (1997).
   PubMed Web of Science ®Google Scholar
• Wurtman R.J. Melatonin. In: Encyclopedia of Dietary Supplements. Coates P (Ed.), Marcel Dekker, 457–466 (2005).
   Google Scholar
• Dollins AB, Zhdanova IV, Wurtman RJ et al. Effect of inducing nocturnal serum melatonin concentration in daytime on sleep, mood, body temperature and performance. Proc. Natl. Acad. Sci. USA91, 1824–1828 (1994).
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ. Efficacy of melatonin as a sleep-promoting agent. J. Biol. Rhythms112, 644–650 (1997).
   Google Scholar
• Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, LeClair OU. Melatonin treatment for age-related insomnia. J. Clin. Endocrin. Metab.86(10), 4727–4730 (2001).
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Vangel MG, Wurtman RJ et al. Effect of exogenous melatonin on sleep – a meta-analysis of 14 controlled clinical trials. Sleep Med. Rev.9, 41–50 (2005).
   PubMed Web of Science ®Google Scholar
• Stone BM, Turner C, Mills SL, Nicholson AN. Hypnotic activity of melatonin. Sleep23, 663–669 (2000).
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Lynch HJ et al. Sleep-inducing effects of low-doses of melatonin ingested in the evening. Clin. Pharmacol. Ther.57, 657–665 (1997).
   Google Scholar
• Haimov I, Laudon M, Zisapel N et al. Sleep disorders and melatonin rhythms in elderly people. BMJ309, 167 (1994).
   PubMed Web of Science ®Google Scholar
• Touitou Y. Some aspects of the circadian time structure in the elderly. Gerontology28(Suppl. 1), 53–67 (1982).
   PubMed Web of Science ®Google Scholar
• Iguchi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J. Clin. Endocrinol. Metab.55, 27–29 (1982).
   PubMed Web of Science ®Google Scholar
• Zhdonova IV, Wurtman RJ, Balcioglu A, Kartashov A, Lynch HJ. Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J. Gerontol.53A, B293–B298 (1998).
   Google Scholar
• Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. J. Pineal Res.3, 379–388 (1986).
   PubMed Web of Science ®Google Scholar
• Gerdin MJ, Masana MI, Dubocovich ML. Melatonin-mediated regulation of human MT1 melatonin receptors expressed in mammalian cells. Biochemical Pharmacology67, 2023–2030 (2004).
   PubMed Web of Science ®Google Scholar
• Gerdin MJ, Masana MI, Rivera-Bermudez MA et al. Melatonin desensitizes endogenous MT2 receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J.18(14), 1646–1656 (2004).
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology48, 301–310 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson S, Bryson S, Amakye D et al. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin. Pharmacol. Ther.75, 22 (2004).
   Web of Science ®Google Scholar
• McGechan A, Wellington K. Ramelteon. CNS Drugs19, 1057–1065 (2005).
   PubMed Web of Science ®Google Scholar
• Cajochen TC. TAK-375. Curr. Opin. Inves. Drugs6, 114–121 (2005).
   PubMedGoogle Scholar
• ROZEREM™ (ramelteon) Tablets. Package Insert (2005).
   Google Scholar
• No authors listed. Ramelteon (Rozerem) for insomnia. The Medical Letter On Drugs and Therapeutics47(1221), 89–91 (2005).
   PubMed Web of Science ®Google Scholar
• Roth T, Stubbs C, Walsk JK. Ramelteon (TAK-375). A selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep28, 303–307 (2005).
   PubMed Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med.7, 17–24 (2006).
   PubMed Web of Science ®Google Scholar
• Zammit G, Roth T, Erman M, Sainati S, Weigand S, Zhang J. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep28(Suppl.) 0680 (2005).
   Google Scholar
• Roth T, Seiden D, Zee P et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients (abstract A21). J. Am. Geriatr. Soc.53, S25 (2005).
   Google Scholar
• Zammit G, Schwartz H, Roth T, Wright L, Sainati S, Zhang J. Phase III study of ramelteon in a first-night-effect model of transient insomnia. Sleep Med.550, O007 (2005).
   Google Scholar
• Witt-Enderby P, Bennett J, Jarzynka M, Firestine S, Melan M. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sciences72, 2183–2198 (2003).
   PubMed Web of Science ®Google Scholar
• Gauer F, Masson-Pevet M, Skene D, Vivien-Roels B, Pevet P. Daily rhythms of melatonin binding sites in the rat pars tuberalis and suprachiasmatic nucleus; evidence for a regulation of melatonin receptors by melatonin itself. Neuroendocrinology57, 120–126 (1993).
   PubMed Web of Science ®Google Scholar
• Hazlerigg D, Gonzalez-Brito A, Lawson W, Hastings M, Morgan P. Prolonged exposure to melatonin leads to time-dependent sensitization of adenylate cyclase and down-regulates melatonin receptors in pars tuberalis cells from ovine pituitary. Endocrinology132, 285–292 (1993).
   PubMed Web of Science ®Google Scholar
• Jones M, Melan M, Witt-Enderby P. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Letters151, 133–143 (2000).
   PubMed Web of Science ®Google Scholar
• Witt-Enderby P, MacKenzie R, McKeon R, Carroll E, Bordt S, Melan M. Melatonin induction of filamentous structures in non-neuronal cells that is dependent on the expression of the human mt1 melatonin receptor. Cell Motil. Cytoskeleton46, 28–42 (2000).
   PubMed Web of Science ®Google Scholar
• Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinine reductase 2. J. Biol. Chem.275, 31311–31317 (2000).
   PubMed Web of Science ®Google Scholar
• Griffiths R, Suess P, Johnson M. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep28(Suppl.) 0132 (2005).
   Google Scholar
• Arendt J. Importance and relevance of melatonin to human biological rhythms. J. Neuroendocrinol.15, 427–431 (2003).
   PubMed Web of Science ®Google Scholar
• Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cochrane Database Syst. Rev.(1), CD001520 (2001).
   Google Scholar
• Zhdanova IV, Wurtman RJ, Morabito C et al. Effects of low oral doses of melatonin, given 2–4 h before habitual bedtime, on sleep in normal young humans. Sleep19, 423–431 (1996).
   PubMed Web of Science ®Google Scholar
• Deacon S, Arendt J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res.688, 77–85 (1995).
   PubMed Web of Science ®Google Scholar
• Arendt J, Aldhous M, Wright J. Synchronization of a disturbed sleep-wake cycle in a blind man by melatonin treatment. Lancet772–773 (1988).
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Emens JS, Lefler BJ et al. Melatonin entrains free-running blind people according to a physiological dose–response curve. Chronobiol. Int.22, 1093–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Arendt J. Jet-lag and shift work: (2) therapeutic use of melatonin. J. Royal Soc. Med.92, 402–406 (1999).
   PubMed Web of Science ®Google Scholar
• Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag (Cochrane Review). In: The Cochrane Library Issue 4, John Wiley & Sons, UK (2003).
   Google Scholar
• Buscemi N, Vandermeer B, Hooton N et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ332, 385–393 (2006).
   PubMed Web of Science ®Google Scholar
• Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol.56, 359–384 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res.36, 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Duell PB, Wheaton DL, Shultz A, Nguyen H. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations. Clin. Chem.44, 9 (1998).
   Google Scholar
• Cagnacci A, Cannoletta M, Renzi A et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens.18, 1614–1618 (2005).
   PubMed Web of Science ®Google Scholar